Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02729961
Title Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Washington

anaplastic large cell lymphoma


Brentuximab vedotin + Ceritinib

Age Groups: adult | child
Covered Countries USA

Additional content available in CKB BOOST